Developer docs
API playgroundTry for free, no card

Search company profiles

OPIA Technologies

Full company profile

uuid000jugo

Namestring
OPIA Technologies
Legal namestring
OPIA Technologies SAS
Websiteurl
opiatech.com
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic medical devices, ocular surface diagnostics, tear film sampling, ocular iontophoresis, conjunctival impression cytology
Industry1 code
PRIMARYHLAHAJAF
Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code3 codes
  • Ophthalmic Goods Manufacturing339115
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Ophthalmic Goods3851
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of proprietary ophthalmic medical devices including EYEPRIM, TEARPRIM, and IONTOFOR-VET product lines. Products are classified medical devices sold to healthcare providers and veterinary clinics.

opiatech.com
2R&D and Regulatory Services
TypeProfessional Services
Description

Provides R&D and regulatory services for medical devices companies. Encompasses support from early-stage idea or proof-of-concept to pilot production or volume manufacturing, including regulatory and quality conformity services.

opiatech.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1EYEPRIM™
Description

Sterile medical device for conjunctival impressions enabling analysis of cells and biomarkers for diagnosis of ocular surface disorders such as dry eye, allergies, or infections.

opiatech.com
+3 more records
Core offering1 text field

OPIA Technologies designs, manufactures and sells proprietary ophthalmic medical devices for sampling ocular surface components (conjunctiva, tear film) and for non-invasive ocular drug delivery via iontophoresis. Its marketed products include EYEPRIM™, TEARPRIM™, IONTOFOR-VET and IONTOFOR-VET Electrode, all backed by proprietary patents and an ISO 13485 quality management system. The company also provides R&D and regulatory services for medical device and pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • IONTOFOR-VET reduces PACK-CXL soaking phase from 30 minutes to 5 minutes
+2 more records
Product overview1 text field

OPIA Technologies is a medical device company developing a portfolio of ophthalmic devices for sampling ocular surface components and non-invasive ocular drug delivery, based on proprietary patents. The product portfolio comprises four distinct medical devices: EYEPRIM™ (conjunctival impression device for cell/biomarker sampling, Class I sterile), TEARPRIM™ (tear film sampling device, Class IIa sterile), IONTOFOR-VET (complete iontophoresis administration set for veterinary PACK-CXL with Riboflavin), and IONTOFOR-VET Electrode (veterinary iontophoresis administration set compatible with multiple drug classes). EYEPRIM™ and TEARPRIM™ are CE-marked and FDA-exempt sampling tools for ocular surface diagnosis, while IONTOFOR-VET products are veterinary iontophoresis delivery systems. The company also has two pipeline devices under development for ocular surface and retinal disorders, and provides R&D and regulatory services for other medical device companies.

Product and service5 records
1EYEPRIM™
CategoryOphthalmic Diagnostic Devices
Description

EYEPRIM™ is a sterile Class I medical device designed to perform conjunctival impressions of the living eye, enabling collection of cells and biomarkers for cytology, cytometry, and PCR analysis to diagnose ocular surface disorders such as dry eye, allergies, and infections. It is CE 0051 (IMQ) certified under directive 93/42/CEE and FDA exempted from Premarket Authorization (21CFR880.6025). Used by ophthalmologists and in clinical studies in the US and Europe.

2TEARPRIM™
CategoryOphthalmic Diagnostic Devices
Description

TEARPRIM™ is a sterile Class IIa medical device designed to sample the tear film, enabling analysis of tear components for diagnosing ocular surface disorders such as dry eye and allergies. It replaces tedious and non-standardized capillary tube and Schirmer strip techniques with a nearly painless, minimally invasive collection of high-quantity tears. It is CE 0051 (IMQ) certified under directive 93/42/CEE and was developed in collaboration with Quinze-Vingts Hospital.

3IONTOFOR-VET
CategoryVeterinary Ophthalmic Drug Delivery Devices
Description

IONTOFOR-VET is a complete veterinary administration set that delivers Riboflavin (Ribovet) into the corneal stroma via iontophoresis for the PACK-CXL (photo-activated chromophore corneal cross-linking) procedure treating infectious keratitis. It includes a corneal applicator, a vial of Ribovet and a vacuum syringe, and reduces the soaking phase from 30 minutes to 5 minutes without removing the epithelium. For use with the I-ON CXL current generator and a UV-A 370nm light source. Veterinary use only.

4IONTOFOR-VET Electrode
CategoryVeterinary Ophthalmic Drug Delivery Devices
Description

IONTOFOR-VET Electrode is a veterinary administration set that allows iontophoresis delivery of a wide array of products — including antibiotics (Vancomycin, Amikacin, Ciprofloxacin, etc.), antifungals (Ketoconazole, Miconazole), antivirals (Foscarnet, Ganciclovir) and anti-inflammatories (Dexamethasone, Methylprednisolone) — into the corneal stroma. Includes a corneal applicator and vacuum syringe. Must be used with the I-ON CXL current generator. Veterinary use only.

5R&D and Regulatory Services for Medical Devices
CategoryContract R&D and Regulatory Services
Description

R&D and regulatory services for medical device and pharmaceutical companies, spanning the full device lifecycle from early-stage idea or proof-of-concept to pilot production or volume manufacturing, including regulatory and quality conformity support under the company's ISO 13485 quality management system.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1JB TECNICS
Strategic tierCoreTypeStrategic or Co-development Partner
Description

JB TECNICS is a worldwide group specialized in tool manufacturing and clean room molding for the medical industry. OPIA Technologies benefits from a privileged relationship with JB TECNICS for developing turnkey solutions for medical devices manufacturing. This partnership provides OPIA with manufacturing capabilities and clean room facilities essential for medical device production.

opiatech.com
2Vision Institute (Paris)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

OPIA Technologies is located at the Vision Institute in Paris, a major ophthalmology research center. This provides proximity to research expertise and clinical collaboration opportunities.

opiatech.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TEARPRIM was developed in close collaboration with Quinze-Vingts Hospital and ophthalmologists. EYEPRIM originated from an idea suggested by Christophe Baudouin, MD, PhD, Chairman of Department of Ophthalmology III at Quinze-Vingts Hospital and Research team leader at Vision Institute Team S12, Inserm-UPMC Research Center 968.

4Christophe Baudouin
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Christophe Baudouin, MD, PhD, Chairman of Department of Ophthalmology III at Quinze-Vingts Hospital, suggested the original idea for EYEPRIM device. He is Research team leader at Vision Institute, Team S12, Inserm-UPMC Research Center 968.

opiatech.com
Strategic tierMinorTypeOthers
Description

IMQ is the notified body (CE 0051) that certified OPIA Technologies' medical devices EYEPRIM and TEARPRIM under directive 93/42/CEE.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1CXL Ophthalmics
TypeEmerging player
Description

CXL Ophthalmics focuses on corneal cross-linking and infectious keratitis therapeutics. It is an emerging peer in the same PACK-CXL / cross-linking space where OPIA's IONTOFOR-VET iontophoresis approach is positioned.

2I-ON CXL
TypeDirect peer
Description

I-ON CXL manufactures the iontophoresis current generator that pairs with OPIA's IONTOFOR-VET administration set for PACK-CXL. It is a complementary co-development partner and the closest comparable in veterinary iontophoresis-based cross-linking.

TypeDirect peer
Description

I-MED Pharma offers a portfolio of dry eye and ocular surface diagnostic and therapeutic products sold to ophthalmologists and optometrists. It overlaps with OPIA in standardized ocular surface disorder management tools for clinical practices.

TypeBroad incumbent
Description

Haag-Streit produces ophthalmic diagnostic instruments (slit lamps, imaging, perimeters) used by ophthalmologists and optometrists. It is a broad incumbent in clinical ophthalmic instrumentation that competes for the same clinical-practice budget as OPIA's devices.

TypeBroad incumbent
Description

Bausch + Lomb is a diversified ophthalmic company with pharmaceutical, surgical, and consumer vision care products including dry eye and ocular surface franchises. It represents a broad incumbent with adjacent diagnostic and device exposure to OPIA's markets.

6Tomey Corporation
TypeBroad incumbent
Description

Tomey manufactures ophthalmic diagnostic equipment including specular microscopes, topographers, and ocular surface analyzers sold to clinics and hospitals. It is comparable as a supplier of ophthalmic diagnostic devices that practitioners purchase alongside OPIA's sampling products.

TypeBroad incumbent
Description

Johnson & Johnson Vision operates a large ophthalmic device and pharmaceutical franchise spanning surgical, contact lens, and dry eye categories. It is a broad incumbent that competes for the same ophthalmologist and optometrist customers as OPIA.

TypeBroad incumbent
Description

Alcon is a global ophthalmic medical device and pharmaceutical incumbent with broad dry eye, surgical, and vision care portfolios. It is a broad incumbent whose diagnostic and surgical device lines overlap with OPIA's ocular surface and ophthalmic device offerings.

9TearLab Corporation
TypeDirect peer
Description

TearLab developed the TearLab Osmolarity System, a point-of-care diagnostic for dry eye that quantifies tear osmolarity. It is directly comparable to OPIA's EYEPRIM and TEARPRIM as a device-based dry eye diagnostic aimed at ophthalmologists and optometrists.

10Rapid Pathogen Screening (RPS Diagnostics)
TypeDirect peer
Description

RPS commercializes InflammaDry, a rapid point-of-care MMP-9 test for ocular surface inflammation. It competes with OPIA's EYEPRIM as an alternative diagnostic workflow for identifying ocular surface disease in eye care practices.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OPIA Technologies

Ophthalmic Medical Devicesopiatech.com

OPIA Technologies firmographics

Firmographics
Name
OPIA Technologies
Legal name
OPIA Technologies SAS
Website
https://opiatech.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

OPIA Technologies industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAJAF
Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Ophthalmic medical devices
  • Ocular surface diagnostics
  • Tear film sampling
  • Ocular iontophoresis
  • Conjunctival impression cytology

Where OPIA Technologies is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

OPIA Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Sale of proprietary ophthalmic medical devices including EYEPRIM, TEARPRIM, and IONTOFOR-VET product lines. Products are classified medical devices sold to healthcare providers and veterinary clinics.
  2. R&D and Regulatory Services: Provides R&D and regulatory services for medical devices companies. Encompasses support from early-stage idea or proof-of-concept to pilot production or volume manufacturing, including regulatory and quality conformity services.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

OPIA Technologies product offering

Product offering

Core offering

OPIA Technologies designs, manufactures and sells proprietary ophthalmic medical devices for sampling ocular surface components (conjunctiva, tear film) and for non-invasive ocular drug delivery via iontophoresis. Its marketed products include EYEPRIM™, TEARPRIM™, IONTOFOR-VET and IONTOFOR-VET Electrode, all backed by proprietary patents and an ISO 13485 quality management system. The company also provides R&D and regulatory services for medical device and pharmaceutical companies.

Product overview

OPIA Technologies is a medical device company developing a portfolio of ophthalmic devices for sampling ocular surface components and non-invasive ocular drug delivery, based on proprietary patents. The product portfolio comprises four distinct medical devices: EYEPRIM™ (conjunctival impression device for cell/biomarker sampling, Class I sterile), TEARPRIM™ (tear film sampling device, Class IIa sterile), IONTOFOR-VET (complete iontophoresis administration set for veterinary PACK-CXL with Riboflavin), and IONTOFOR-VET Electrode (veterinary iontophoresis administration set compatible with multiple drug classes). EYEPRIM™ and TEARPRIM™ are CE-marked and FDA-exempt sampling tools for ocular surface diagnosis, while IONTOFOR-VET products are veterinary iontophoresis delivery systems. The company also has two pipeline devices under development for ocular surface and retinal disorders, and provides R&D and regulatory services for other medical device companies.

Differentiator

Problem solved

Functional benefit

Brands

  • EYEPRIM™: Sterile medical device for conjunctival impressions enabling analysis of cells and biomarkers for diagnosis of ocular surface disorders such as dry eye, allergies, or infections.
  • TEARPRIM™
  • IONTOFOR-VET
  • IONTOFOR-VET Electrode

Products and services

  • EYEPRIM™ EYEPRIM™ is a sterile Class I medical device designed to perform conjunctival impressions of the living eye, enabling collection of cells and biomarkers for cytology, cytometry, and PCR analysis to diagnose ocular surface disorders such as dry eye, allergies, and infections. It is CE 0051 (IMQ) certified under directive 93/42/CEE and FDA exempted from Premarket Authorization (21CFR880.6025). Used by ophthalmologists and in clinical studies in the US and Europe.
  • TEARPRIM™ TEARPRIM™ is a sterile Class IIa medical device designed to sample the tear film, enabling analysis of tear components for diagnosing ocular surface disorders such as dry eye and allergies. It replaces tedious and non-standardized capillary tube and Schirmer strip techniques with a nearly painless, minimally invasive collection of high-quantity tears. It is CE 0051 (IMQ) certified under directive 93/42/CEE and was developed in collaboration with Quinze-Vingts Hospital.
  • IONTOFOR-VET IONTOFOR-VET is a complete veterinary administration set that delivers Riboflavin (Ribovet) into the corneal stroma via iontophoresis for the PACK-CXL (photo-activated chromophore corneal cross-linking) procedure treating infectious keratitis. It includes a corneal applicator, a vial of Ribovet and a vacuum syringe, and reduces the soaking phase from 30 minutes to 5 minutes without removing the epithelium. For use with the I-ON CXL current generator and a UV-A 370nm light source. Veterinary use only.
  • IONTOFOR-VET Electrode IONTOFOR-VET Electrode is a veterinary administration set that allows iontophoresis delivery of a wide array of products — including antibiotics (Vancomycin, Amikacin, Ciprofloxacin, etc.), antifungals (Ketoconazole, Miconazole), antivirals (Foscarnet, Ganciclovir) and anti-inflammatories (Dexamethasone, Methylprednisolone) — into the corneal stroma. Includes a corneal applicator and vacuum syringe. Must be used with the I-ON CXL current generator. Veterinary use only.
  • R&D and Regulatory Services for Medical Devices R&D and regulatory services for medical device and pharmaceutical companies, spanning the full device lifecycle from early-stage idea or proof-of-concept to pilot production or volume manufacturing, including regulatory and quality conformity support under the company's ISO 13485 quality management system.

Quantifiable outcome

  • IONTOFOR-VET reduces PACK-CXL soaking phase from 30 minutes to 5 minutes
  • +2 more outcomes

Companies that use OPIA Technologies

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

OPIA Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

OPIA Technologies partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • JB TECNICScoreStrategic or Co-development PartnerJB TECNICS is a worldwide group specialized in tool manufacturing and clean room molding for the medical industry. OPIA Technologies benefits from a privileged relationship with JB TECNICS for developing turnkey solutions for medical devices manufacturing. This partnership provides OPIA with manufacturing capabilities and clean room facilities essential for medical device production.
  • Vision Institute (Paris)coreStrategic or Co-development PartnerOPIA Technologies is located at the Vision Institute in Paris, a major ophthalmology research center. This provides proximity to research expertise and clinical collaboration opportunities.
  • Quinze-Vingts HospitalcoreStrategic or Co-development PartnerTEARPRIM was developed in close collaboration with Quinze-Vingts Hospital and ophthalmologists. EYEPRIM originated from an idea suggested by Christophe Baudouin, MD, PhD, Chairman of Department of Ophthalmology III at Quinze-Vingts Hospital and Research team leader at Vision Institute Team S12, Inserm-UPMC Research Center 968.
  • Christophe BaudouinminorStrategic or Co-development PartnerChristophe Baudouin, MD, PhD, Chairman of Department of Ophthalmology III at Quinze-Vingts Hospital, suggested the original idea for EYEPRIM device. He is Research team leader at Vision Institute, Team S12, Inserm-UPMC Research Center 968.
  • IMQ (Istituto Marchio Qualità)minorOthersIMQ is the notified body (CE 0051) that certified OPIA Technologies' medical devices EYEPRIM and TEARPRIM under directive 93/42/CEE.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

OPIA Technologies competitors and assessment

Company assessment

Emerging players

  • CXL Ophthalmics: CXL Ophthalmics focuses on corneal cross-linking and infectious keratitis therapeutics. It is an emerging peer in the same PACK-CXL / cross-linking space where OPIA's IONTOFOR-VET iontophoresis approach is positioned.

Direct peers

  • I-ON CXL: I-ON CXL manufactures the iontophoresis current generator that pairs with OPIA's IONTOFOR-VET administration set for PACK-CXL. It is a complementary co-development partner and the closest comparable in veterinary iontophoresis-based cross-linking.
  • I-MED Pharma: I-MED Pharma offers a portfolio of dry eye and ocular surface diagnostic and therapeutic products sold to ophthalmologists and optometrists. It overlaps with OPIA in standardized ocular surface disorder management tools for clinical practices.
  • TearLab Corporation: TearLab developed the TearLab Osmolarity System, a point-of-care diagnostic for dry eye that quantifies tear osmolarity. It is directly comparable to OPIA's EYEPRIM and TEARPRIM as a device-based dry eye diagnostic aimed at ophthalmologists and optometrists.
  • Rapid Pathogen Screening (RPS Diagnostics): RPS commercializes InflammaDry, a rapid point-of-care MMP-9 test for ocular surface inflammation. It competes with OPIA's EYEPRIM as an alternative diagnostic workflow for identifying ocular surface disease in eye care practices.

Broad incumbents

  • Haag-Streit Group: Haag-Streit produces ophthalmic diagnostic instruments (slit lamps, imaging, perimeters) used by ophthalmologists and optometrists. It is a broad incumbent in clinical ophthalmic instrumentation that competes for the same clinical-practice budget as OPIA's devices.
  • Bausch + Lomb: Bausch + Lomb is a diversified ophthalmic company with pharmaceutical, surgical, and consumer vision care products including dry eye and ocular surface franchises. It represents a broad incumbent with adjacent diagnostic and device exposure to OPIA's markets.
  • Tomey Corporation: Tomey manufactures ophthalmic diagnostic equipment including specular microscopes, topographers, and ocular surface analyzers sold to clinics and hospitals. It is comparable as a supplier of ophthalmic diagnostic devices that practitioners purchase alongside OPIA's sampling products.
  • Johnson & Johnson Vision: Johnson & Johnson Vision operates a large ophthalmic device and pharmaceutical franchise spanning surgical, contact lens, and dry eye categories. It is a broad incumbent that competes for the same ophthalmologist and optometrist customers as OPIA.
  • Alcon: Alcon is a global ophthalmic medical device and pharmaceutical incumbent with broad dry eye, surgical, and vision care portfolios. It is a broad incumbent whose diagnostic and surgical device lines overlap with OPIA's ocular surface and ophthalmic device offerings.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

OPIA Technologies compliance and trust

Trust signal

Compliance3 records

OPIA Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OPIA Technologies leadership team

Management profile

Number of profiles

Profiles1 record

OPIA Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OPIA Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OPIA Technologies

What does OPIA Technologies do?

OPIA Technologies designs, manufactures and sells proprietary ophthalmic medical devices for sampling ocular surface components (conjunctiva, tear film) and for non-invasive ocular drug delivery via iontophoresis. Its marketed products include EYEPRIM™, TEARPRIM™, IONTOFOR-VET and IONTOFOR-VET Electrode, all backed by proprietary patents and an ISO 13485 quality management system. The company also provides R&D and regulatory services for medical device and pharmaceutical companies.

Is OPIA Technologies a public or private company?

OPIA Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was OPIA Technologies founded?

OPIA Technologies was founded in 2015. It employs 1 to 10 people.

Where is OPIA Technologies based?

OPIA Technologies is headquartered in Paris, France, in the Europe region.

How does OPIA Technologies make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are R&D and Regulatory Services.

Who are OPIA Technologies's main competitors?

CXL Ophthalmics is listed as an emerging player. Direct peers are I-ON CXL, I-MED Pharma, TearLab Corporation and Rapid Pathogen Screening (RPS Diagnostics). Broad incumbents are Haag-Streit Group, Bausch + Lomb, Tomey Corporation, Johnson & Johnson Vision and Alcon.

Does OPIA Technologies have an API?

No public API is recorded for OPIA Technologies.

What industry is OPIA Technologies in?

OPIA Technologies's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAF, Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales